Dupont Capital Management Corp Has $7.76 Million Stock Position in Danaher Co. (NYSE:DHR)

Dupont Capital Management Corp decreased its stake in Danaher Co. (NYSE:DHR) by 13.9% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 33,801 shares of the conglomerate’s stock after selling 5,472 shares during the period. Dupont Capital Management Corp’s holdings in Danaher were worth $7,759,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also modified their holdings of the stock. Daymark Wealth Partners LLC boosted its stake in Danaher by 0.9% during the fourth quarter. Daymark Wealth Partners LLC now owns 17,521 shares of the conglomerate’s stock worth $4,022,000 after buying an additional 155 shares in the last quarter. Albion Financial Group UT boosted its stake in Danaher by 360.7% during the fourth quarter. Albion Financial Group UT now owns 1,290 shares of the conglomerate’s stock worth $296,000 after buying an additional 1,010 shares in the last quarter. Beaumont Financial Advisors LLC boosted its stake in Danaher by 59.4% during the fourth quarter. Beaumont Financial Advisors LLC now owns 2,958 shares of the conglomerate’s stock worth $679,000 after buying an additional 1,102 shares in the last quarter. Bourgeon Capital Management LLC boosted its stake in Danaher by 7.4% during the fourth quarter. Bourgeon Capital Management LLC now owns 60,178 shares of the conglomerate’s stock worth $13,814,000 after buying an additional 4,150 shares in the last quarter. Finally, Roberts Wealth Advisors LLC boosted its stake in Danaher by 18.8% during the fourth quarter. Roberts Wealth Advisors LLC now owns 950 shares of the conglomerate’s stock worth $226,000 after buying an additional 150 shares in the last quarter. Institutional investors and hedge funds own 79.05% of the company’s stock.

Danaher Stock Performance

Shares of NYSE:DHR opened at $244.19 on Thursday. The stock has a market capitalization of $176.38 billion, a P/E ratio of 46.60, a P/E/G ratio of 4.30 and a beta of 0.83. Danaher Co. has a 1-year low of $225.42 and a 1-year high of $281.70. The company has a current ratio of 1.37, a quick ratio of 1.01 and a debt-to-equity ratio of 0.32. The business has a 50-day moving average price of $234.84 and a two-hundred day moving average price of $253.53.

Danaher (NYSE:DHR) last announced its quarterly earnings results on Tuesday, October 22nd. The conglomerate reported $1.71 EPS for the quarter, beating analysts’ consensus estimates of $1.57 by $0.14. The company had revenue of $5.80 billion during the quarter, compared to analysts’ expectations of $5.59 billion. Danaher had a return on equity of 10.62% and a net margin of 16.39%. Danaher’s revenue was up 3.1% on a year-over-year basis. During the same period in the prior year, the business posted $2.02 EPS. Equities analysts predict that Danaher Co. will post 7.49 earnings per share for the current year.

Danaher Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, January 31st. Stockholders of record on Friday, December 27th will be paid a $0.27 dividend. The ex-dividend date of this dividend is Friday, December 27th. This represents a $1.08 dividend on an annualized basis and a dividend yield of 0.44%. Danaher’s dividend payout ratio (DPR) is presently 20.61%.

Analyst Upgrades and Downgrades

A number of research firms have weighed in on DHR. Robert W. Baird decreased their price target on shares of Danaher from $278.00 to $277.00 and set an “outperform” rating on the stock in a research note on Wednesday, October 23rd. Evercore ISI boosted their target price on shares of Danaher from $275.00 to $278.00 and gave the company an “outperform” rating in a research note on Tuesday, October 1st. Royal Bank of Canada reduced their target price on shares of Danaher from $333.00 to $311.00 and set an “outperform” rating on the stock in a research note on Wednesday, October 23rd. Scotiabank assumed coverage on shares of Danaher in a research note on Monday, December 23rd. They issued a “sector perform” rating and a $265.00 target price on the stock. Finally, StockNews.com downgraded shares of Danaher from a “buy” rating to a “hold” rating in a research note on Saturday, December 14th. Six research analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $285.55.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.